Acknowledgements

Mrs. Judith de Grauw assisted with baseline copyediting of this chapter.

[7] Hughes L, Guthrie S. Operationalization of global Alzheimer's disease trials A2—Bairu, Menghis. In: Weiner M, editor. Global Clinical Trials for Alzheimer's Disease. San Diego:

Challenges in Dementia Studies

125

http://dx.doi.org/10.5772/intechopen.72866

[8] Petersen R. Does the source of subjects matter?: Absolutely. Neurology. 2010 Jun 1;74(22):

[9] Schneider J, Arvanitakis Z, Bang W, Bennett D. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204

[10] Rowe C, Ellis K, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging. 2010;31(8):1275-1283

[11] Petersen R, Aisen P, Beckett L, et al. Alzheimer's Disease Neuroimaging Initiative

[12] Trahan L, Stuebing K, Hiscock M, Fletcher J. The Flynn effect: A meta-analysis. Psychological Bulletin. 2014 Sep;140(5):1332-1360. Epub 2014 Jun 30. DOI: 10.1037/a0037173 [13] Westman E, Muehlboeck J, Simmons A, Combining MRI. CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. NeuroImage.

[14] Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI.

[15] Ewers M, Walsh C, Trojanowski J, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsycho-

[16] Gomar J, Bobes-Bascaran M, Conejero-Goldberg C, Davies P, Goldberg T. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroim-

[17] Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to

[18] Ho A, Hua X, Lee S, et al. Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Human Brain Mapping. 2010;31(4):499-514

[19] Grothe M, Kurth J, Hampel H, Krause B, Teipel S. Chapter 9—Standardization of MRI and amyloid imaging A2—Bairu, Menghis. In: Weiner MW, editor. Global Clinical Trials

[20] Lo R, Jagust W. Predicting missing biomarker data in a longitudinal study of Alzheimer

[21] Satagopan J, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach A. A note on competing risks in survival data analysis. British Journal of Cancer. 2004;91(7):1229-1235

Alzheimer's disease using multivariate predictors. PLoS One. 2011;6(7):21

for Alzheimer's Disease. San Diego: Academic Press; 2014. pp. 131-156

logical test performance. Neurobiology of Aging. 2012;33(7):1203-1214

aging initiative. Archives of General Psychiatry. 2011;68(9):961-969

1754-1755. DOI: 10.1212/WNL.0b013e3181e533e7. Epub 2010 May 19

(ADNI): Clinical characterization. Neurology. 2010;74(3):201-209

Academic Press; 2014. pp. 159-177

2012;62(1):229-238

NeuroImage. 2009;44(4):1415-1422

disease. Neurology. 2012;78(18):1376-1382
